Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2021 09:43 ET | Source: Junshi Biosciences

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

SHANGHAI, China, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
December 05, 2021 18:06 ET | Source: Junshi Biosciences

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
December 03, 2021 07:53 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List

SHANGHAI, China, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
November 29, 2021 20:00 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products...
November 15, 2021 08:30 ET | Source: Junshi Biosciences

Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences,...
November 01, 2021 08:00 ET | Source: Junshi Biosciences

TopAlliance Appoints Virginia Ellen Maher, MD, as Vice President of Medical Sciences

SHANGHAI, China, Nov. 01, 2021 (GLOBE NEWSWIRE) -- TopAlliance Biosciences, a wholly own subsidiary of Junshi Biosciences (HKEX: 1877; SSE: 688180) today announced the appointment of Dr. Virginia...
November 01, 2021 07:30 ET | Source: Junshi Biosciences

Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma

SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
September 19, 2021 07:29 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
September 16, 2021 20:19 ET | Source: Junshi Biosciences

Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

– Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 – – Data support the use of toripalimab with chemotherapy as first-line therapy...
September 15, 2021 08:30 ET | Source: Junshi Biosciences

Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine

SHANGHAI and REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”,...